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p-Mentha-1,8-dien-7-al is a naturally occurring cyclic alpha,beta-unsaturated aldehyde that is used as a
ﬂavoring substance throughout the world. Due to the chemical structure and the potential DNA reactivity
of the alpha,beta-unsaturated carbonyl moiety, a battery of genotoxicity assays was requested by the
European Food Safety Authority. Previous genotoxicity studies on the substance gave mixed results, but
both positive and negative results were hampered by not always being performed to any standard
guideline. The new test battery data indicated some evidence of mutagenicity in vitro, but an in vivo
comet/micronucleus combination assay performed in rats was concluded by the study directors to not
result in any biologically relevant positive responses. However, EFSA concluded that the in vivo assay
gave evidence that p-mentha-1,8-dien-7-al was of potential genotoxic concern. The Expert Panel of the
Flavor and Extract Manufacturers Association (FEMA) has reviewed the newly available data and
considered its interpretation relative to standard guidelines such as that established by the Organization
for Economic Cooperation and Development, and has concluded that the results in the comet/micro-
nucleus combination assay are consistent with the interpretation by the study directors; namely, that p-
mentha-1,8-dien-7-al does not appear to have any in vivo genotoxic potential.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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A number of genotoxicity tests have been developed and vali-
dated over time that can provide relevant information regarding
the potential of a substance to damage DNA. Yet, no single test is
sufﬁcient in isolation to provide deﬁnitive answers to the question
of whether a substance is genotoxic or not. Hence, scientiﬁc bodies
and regulators alike have recognized the value of a genotoxicity
testing battery that includes a minimum set of assays, whether
in vitro or in vivo, each with the power to reveal different modes of
genotoxic potential.
Considering the strengths and speciﬁc parameters that each
type of genotoxicity assay offers, most testing batteries that are
now used to address the genotoxic potential of chemicals, including
a variety of food ingredients, include a combination adequate to
thoroughly assess genotoxic potential. Regulatory guidelines in the
US (Redbook) and Europe (European Food Safety Authority (EFSA)
Genotoxicity Testing Guidelines) have been developed to specify
the minimum set of complementary tests to obtain a complete
picture of potential genotoxicity for food substances, covering three
genotoxicity endpoints, namely mutagenicity, structural (clasto-
genicity), and numerical (aneugenicity) chromosomal aberrations
(FDA, 2007; EFSA, 2011). Similar genotoxicity testing batteries have
been developed for pharmaceutical substances (ICH, 2011).
For most food ingredients, a basic battery typically includes an
in vitro test of mutagenic potential and an in vitro genotoxicity test
that addresses the potential for clastogenic and/or aneugenic ef-
fects. Speciﬁcally, studies to investigate gene (point) mutations
include a) a bacterial reverse mutation test in Salmonella typhi-
murium and Escherichia coli [Organization for Economic Coopera-
tion and Development Testing Guideline (OECD TG) 471] and b) an
in vitro mammalian cell gene mutation test (OECD TG 476); and
studies to investigate chromosome aberrations include a) an in vitro
mammalian chromosomal aberration test (OECD 473) and b) an
in vitromammalian cell micronucleus test (OECD TG 487). Of these,
the bacterial reverse mutation test (OECD TG 471) and the in vitro
mammalian cell micronucleus test (OECD TG 487) are the most
common in vitro set required for regulatory testing. This set may be
modiﬁed or abandoned if there are reasons to consider it insufﬁ-
cient, such as evidence that speciﬁc metabolic pathways for a
certain substance occurring in humans are absent in the in vitro test
system, or that the in vitro test system is inappropriate on grounds
of physicochemical properties of the substance or of its mode of
action.
Following up in vitro testing with in vivo assays is generally
neither needed nor encouraged if results of in vitro tests are clearly
negative. However, where positive or unclear results are collected
from one or more in vitro test systems, they may be followed withan appropriate in vivo assay that further assesses the biological
relevance of the in vitro ﬁndings in vivo. In light of equivocal and
especially positive responses in the in vitro tests, selected in vivo
tests are recommended based on the type of genotoxic endpoint
that needs further resolution, speciﬁcally, a) a mammalian eryth-
rocyte micronucleus test (OECD TG 474) to follow up an equivocal
or positive in vitro micronucleus test; this may be substituted by a
bone marrow chromosomal aberrations test (OECD TG 475); b)
transgenic rodent somatic and germ cell gene mutation assays
(OECD TG 488) to follow up equivocal or positive in vitro mutage-
nicity assays; and c) an in vivo comet assay (OECD TG 489); this is
considered a useful “indicator” test to follow up equivocal or pos-
itive in vitro mutagenicity or clastogenicity (but not aneugenicity)
results.
Each genotoxicity assay has been thoroughly evaluated by
groups of experts who have reached consensus on the methodo-
logical details, the evaluation and acceptance criteria of test validity
and a set of criteria for the interpretation of results, including sta-
tistical analysis. Collectively the consensus conclusions on the
utility, strengths, limitations, and performance of the assay are
made public in the form of OECD Guidelines, which are periodically
updated and reﬁned as new information or experience with the
conduct of the assays becomes available. The intent of the Guide-
lines is to provide a set ofminimumquality criteria for each assay so
that when performed by any investigator anywhere in the world
they can provide results that are directly comparable to those of
similarly run assays. More importantly, the Guidelines intend to lay
down speciﬁc criteria for the interpretation of results. One readily
appreciates the challenge of drawing conclusions about the bio-
logical properties of a chemical substancedgenotoxicity in this
casedwhen considering the complexity of biological systems. Re-
sults that are clearly negative or clearly positive present no chal-
lenge. Biological deviations, however, can result in artefacts in the
test system and this is where the utmost scientiﬁc rigor and a solid
understanding of the system and the assay performed are para-
mount to reaching scientiﬁcally justiﬁable conclusions. The possi-
bility of randomness in biological events can generally be
controlled to an extent by the application of statistical procedures
to assist in interpreting variations by providing a gauge of the
likelihood that they are truly random. The OECD Guidelines
recognise this and prescribe appropriate statistical applications.
Statistical analysis appropriate for the type of data is applied to
determine whether a variation from what is naturally variable is
large enough (magnitude of change) to be considered non-random
and an effect of the test conditions, such as the presence of the test
substance. This is determined both against the variation within the
speciﬁc assay by comparing the treatment to the internal or con-
current control, but also against the variation that the system has
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performed, indicated as a range of “normal” outcomes, or the his-
torical vehicle control range. In every OECD Guideline these ele-
ments are present without exception, revealing the consensus
understanding by experts in all areas of genotoxicity testing of the
challenges in interpreting randomness and biological variability
within experiments.
Despite the consensus to explicitly establish criteria for the
interpretation of assay results, unintentional violations can still
occur. Within this commentary, the FEMA Expert Panel evaluates
the available genotoxicity data for p-mentha-1,8-dien-7-al, which
was also recently the focus of an opinion published by EFSA (EFSA,
2015). In that opinion, EFSA concluded that the substance, based on
the available data, demonstrated genotoxic potential. In the review
provided here, the FEMA Expert Panel has concluded that p-men-
tha-1,8-dien-7-al does not raise a concern with respect to geno-
toxicity. The Panel's review of the data, as well as a discussion of the
differing conclusions, is provided.2. The genotoxicity testing proﬁle of p-mentha-1,8-dien-7-al
p-Mentha-1,8-dien-7-al (CAS No. 2111-75-3), also known as
perillaldehyde, is a ﬂavoring substance that is approved for use in
the USA (FEMA No. 3557) and is currently considered of no safety
concern under current conditions of use by the Joint FAO/WHO
Expert Committee on Food Additives. It was considered by EFSA to
be a “representative” substance of a chemical group of 10 alicyclic
aldehydes, alcohols and their esters with the alpha, beta (a,b)-
unsaturation in the ring or side-chain1 (EFSA, 2008). On that basis,
EFSA requested data for p-mentha-1,8-dien-7-al according to their
published genotoxicity testing guidance (EFSA, 2011).
EFSA identiﬁed the feature of a,b-unsaturation as a structural
alert for genotoxicity since it could potentially give rise to reactivity
with cellular nucleophiles, including DNA (EFSA, 2008). EFSA
created a list of more than 300 ﬂavorings based on the a,b-unsa-
turation structural feature or the ability of ﬂavorings to be con-
verted into substances that would contain this structural feature.
This list is referred to as Flavoring Group Evaluation 19 (FGE.19),
which covers all a,b-unsaturated aldehydes or ketones and their
precursors. The FGE.19 list was further divided into subgroups
based on additional structural features, and a group of 10 ﬂavorings,
including p-mentha-1,8-dien-7-al, was allocated to FGE.19 chemi-
cal subgroup 2.2. For subgroup 2.2, EFSA determined that there was
a need for additional information before conclusions on their
genotoxicity could be reached.2.1. Genotoxicity testing (prior to 2010)
2.1.1. In vitro
p-Mentha-1,8-dien-7-al was tested in several in vitro genotox-
icity assays that provided inconsistent information about its gen-
otoxic potential (Fujita et al., 1994; Hayashi et al., 1988; Ishidate
et al., 1984; Kuroda et al., 1984; Sasaki et al., 1990; Suzuki and
Suzuki, 1994; Tayama et al., 1990; Yoo, 1986) (Table 1).
In assays that explored the mutagenic potential, p-mentha-1,8-
dien-7-al was negative in bacterial reverse mutation assays (Ames
assays) in Salmonella typhimurium strains TA92, TA94, TA98, TA100,1 p-Mentha-1,8-dien-7-ol [FL-no: 02.060]; Myrtenol [FL-no: 02.091]; Myrtenal
[FL-no: 05.106]; p-Mentha-1,8-dien-7-al [FL-no: 05.117]; 2,6,6-Trimethyl-1-
cyclohexen-1-carboxaldehyde [FL-no: 05.121]; Myrtenyl formate [FL-no: 09.272];
p-Mentha-1,8-dien-7-yl acetate [FL-no: 09.278]; Myrtenyl acetate [FL-no: 09.302];
Myrtenyl-2-methylbutyrate [FL-no: 09.899]; Myrtenyl-3-methylbutyrate [FL-no:
09.900].TA1535, and TA1537 at concentrations up to 1000 mg/plate, with
and without metabolic activation (Ishidate et al., 1984), or with
S. typhimurium strains TA97 and TA102 at concentrations up to
100 mg/plate, with and without metabolic activation (Fujita et al.,
1994) and with Escherichia coli WP2 at concentrations from 50 to
400 mg/plate in the absence of metabolic activation (inclusion of a
metabolic activation system was not examined) (Yoo, 1986). While
there were no indications of positive results, the concentrations
used in these studies are not consistent with current OECD guide-
lines (OECD, 1997).
In the rec assay with Bacillus subtilis strains M45 (rec) and H17
(recþ), one study reported negative results at concentrations be-
tween 0.16 and 0.63 ml/plate and positive results at higher con-
centrations (1.25e2.5 ml/plate) (Kuroda et al., 1984). In the Rec assay
of Yoo (1986), a weak positive response was seen at the highest
concentration of 2.5 ml/plate (using a speciﬁc density of ~0.965 g/
ml, this is equivalent to ~2400 mg/plate) (Yoo,1986). However, there
was no growth inhibition in the H17 recþ strain (inhibition
zone ¼ 0 mm), and the zone of growth inhibition in M45 rec- was
low (12 mm). It should be noted that the bacterial DNA damage
(Rec) assays are not mutation assays. Therefore, this information
can only be considered as auxiliary.
Negative results were reported in the SOS Chromotest, which
uses genetically engineered E. coli, with a “maximum induction
factor” (Imax) of 1.0 compared to the minimum Imax threshold of
signiﬁcance of 1.5 (Eder et al., 1993). The SOS chromotest is an in-
dicator of DNA damage and strictly not a mutation test. There is no
information on what concentrations were tested, how many rep-
licates etc., and therefore these data are inadequate for assessment.
Inconsistent results have been reported in standard cytogenetic
assays, such as Sister Chromatid Exchange (SCE) and chromosomal
aberration (CA) assays with and without metabolic activation. One
SCE assay, conducted in Chinese hamster ovary cells (CHO-K1),
yielded positive results for genotoxicity at concentrations of
50e100 mg/ml without S-9, and 50e300 mg/ml with S-9, with
cytotoxicity reported at 150 mg/ml in the absence of S-9 (Tayama
et al., 1990), while another SCE assay, also in CHO-K1 cells, yiel-
ded negative results at 10 mg/ml with cytotoxicity reported at
concentrations 12.5 mg/ml (Sasaki et al., 1990). Similarly, one CA
study reported positive results in the Chinese hamster ﬁbroblast
cell line (CHL) at 40 and 50 mg/ml (with 20% and 39% incidence,
respectively) without metabolic activation (Ishidate et al., 1984).
However, in the Ishidate et al. (1984) study, there was no concur-
rent measure of cytotoxicity. Instead, the test concentrations were
selected from a preliminary experiment in which only cell density
was measured as indicator of cytotoxicity, a rather crude and sub-
jective measure. In addition, only single cultures were treated with
each of three concentrations, and therefore only 100 cells from each
concentration and time point were scored for CA, which is signiﬁ-
cantly less than OECD guidelines mandate. In another study using
50e300 mg/ml, CA increases were reported only at the top con-
centrations without and with S-9 (150 mg/ml and 300 mg/ml,
respectively) which were also associated with cytotoxicity (Tayama
et al., 1990). The SCE assays only provide limited information since
the mechanism of SCE induction and its relevance for mutation and
cancer are not well understood.
In a mutation assay conducted in CHO cells using ouabain
resistance as a marker, p-mentha-1,8-dien-7-al was tested at a
single concentration of 10 mg/ml, which reduced survival to 63.5% of
controls (Sasaki et al., 1990). An increase in mutant frequency was
reported (0.7 mutants per 106 cells) versus zero mutations in
controls. This level of mutation is very low and the result would
probably be considered negative. However, the statistical signiﬁ-
cance, dose-dependence, or performance of the assay or the test
substance relative to historical control data were not determined,
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In two mutagenicity studies in human fetal cells (Rsa), positive
results were reported at very low concentrations, based on ouabain
resistance as a mutagenicity indicator. In one study, p-mentha-1,8-
dien-7-al was negative at 10 ng/ml and positive at 15 and 20 ng/ml,
where it induced signiﬁcant (>8-fold, and >15-fold, respectively)
increases in ouabain resistance. It was also negative at a cytotoxic
concentration of 25 ng/ml (Suzuki et al., 1990). In another study
(Suzuki and Suzuki, 1994), p-mentha-1,8-dien-7-al was mutagenic
at >10 ng/ml as determined by ouabain resistance, and at
2e200 ng/ml as determined at K-ras codons, with clear indications
of cytotoxicity at 20 ng/ml and higher. The ouabain resistance locus
is not currently used as a marker for mutagenicity in a regulatory
testing context. In addition, human fetal (Rsa) cells are not
routinely used for genotoxicity testing.Table 1
Genotoxicity proﬁle of perillaldehyde e in vitro studies.
Test-system Test object Concent
Reverse mutation S. typhimurium TA97, TA102 1, 5, 10,
Reverse mutation S. typhimurium TA92, TA1535, TA100, TA1537,
TA94, TA98
Up to 10
Mutagenicity Chinese hamster ovary cells 10, 12.5
Mutagenicity Human fetus cells (Rsa) 0.010 mg
Human fetus cells (Rsa) 0.015 an
Mutagenicity Human fetus cells (Rsa) 2e200 n
Mutagenicity E. coli WP2 50e400
Reverse Mutationa,b S. typhimurium TA100 1.6, 8, 4
S. typhimurium TA102, TA1535, TA1537 0.32, 1.6
S. typhimurium TA98 0.32, 1.6
S. typhimurium TA102, TA1535, TA1537 8.92, 20
5000 mg
S. typhimurium TA98 8.92, 20
5000 mg
S. typhimurium TA98l 0.32, 1.6







Escherichia coli PQ37 Not repo
DNA damage (rec assay) Bacillus subtilis M45 and H17 0.16, 0.3
Bacillus subtilis M45 and H17 1.25 and
DNA damage (rec assay) Bacillus subtilis M45 and H17 2.5 ml/di
Sister chromatid
exchange
Chinese hamster ovary cells 50, 100,
Chinese hamster ovary cells 50, 100,
Chromosomal aberration Chinese hamster ﬁbroblasts 40 and 5
Chromosomal aberration Chinese hamster ovary cells 50, 100,
Chinese hamster ovary cells 50, 100,
Micronucleus Induction Primary human lymphocytes 80, 110,
100, 120
20, 25, a
b With and without metabolic activation.
a Pre-incubation with exogenous metabolic system from rat liver.
c Without metabolic activation.
g Cytotoxic at 12 mg/ml.
h Cytotoxic at 0.025 mg/ml.
i Cytotoxic at > 20 ng/ml.
d Cytotoxic at 150 mg/ml.
e With metabolic activation.
f Positive only at cytotoxic concentrations.
j Cytotoxic  160 mg/ml.
k Cytotoxic  180 mg/ml (3 h treatment in the presence of S9); cytotoxic  100 mg/m
absence of S9).
l A different batch of test article was used and positive results in TA98 were conﬁrme
m At 50 mg/ml: 24h and 48h; and at 40 mg/ml: 24h, including polyploidy.
n Cytotoxicity at 2.5 ul.
o 3 h in the absence of S-9.
p 3 h in the presence of S-9.
q 24 h in the absence of S-9.2.1.2. In vivo
In an in vivo micronucleus assay, p-mentha-1,8-dien-7-al was
administered to eight-week-old male ddY mice via a single intra-
peritoneal injection at doses of 75, 150, 300, or 600 mg/kg bw (6
mice/group) (Table 2). The mice were killed after 24 h and femoral
bone marrow cells were collected and processed for analysis. There
was no evidence of micronucleus induction at any dose level, based
on scoring of 1000 polychromatic erythrocytes per mouse (Hayashi
et al., 1988). It is of interest to note that this in vivo bone marrow
MN test of Hayashi et al. (1988) does not comply with current
guidelines. Speciﬁcally, after a single administration, animals
should be sacriﬁced 24 and 48 h later, and only 1000 PCE were
scored per animal; additionally, parenteral administration is not
physiologically relevant.ration Results Reference
50, and 100 mg/plate Negativea,b Fujita et al. (1994)
00 mg/plate Negativea,b Ishidate et al. (1984)
, 25, 50, and 100 mg/ml Negativec,g Sasaki et al. (1990)
/ml Negative Suzuki et al. (1990)
d 0.020 mg/ml Positiveh
g/ml Positivei Suzuki and Suzuki
(1994)
mg/plate Negative Yoo (1986)
0, 200, 1000 and 5000 mg/plate Negative Bowen (2011)
, 8, 40, 200, 1000 and 5000 mg/plate Negative
, 8, 40, 200, 1000 and 5000 mg/plate Positivec
Negativee
.48, 51.2, 128, 320, 800, 2000, and
/plate
Negative




, 8, 40, 200, 1000 and 5000 mg/plate Positivec
0, 70, 80, 90, and 100 mg/mlo Negativeb Lloyd (2012)
0, 100, 120, 140, 160, and 180 mg/mlk,p
0, 60, 70, 80, 90, 100 and 120 mg/mlo
5, 100, 120, 140, 160, 170, and 180 mg/mlp
15, 18, and 21 mg/mLq
rted Negative Eder et al. (1993)
2, and 0.63 ml Negative Kuroda et al. (1984)
2.5 ml Positiven
sc Weak positive Yoo (1986)
150, and 200 mg/ml Positivec,d Tayama et al. (1990)
150, 200, and 300 mg/ml Positived,e
0 mg/ml Positivec,m Ishidate et al. (1984)
150, 200, and 300 mg/ml Negatived,e,f Tayama et al. (1990)
150, and 200 mg/ml Negativec,d,f
and 120 mg/ml j,o Negativeb Lloyd (2009)
, and 140 mg/mlp
nd 35 mg/mlq
l (3 h treatment in the absence of S9); cytotoxic  21 mg/ml (24 h treatment in the
d.
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Because of the numerous limitations in the earlier genotoxicity
studies, new OECD-compliant genotoxicity studies were conducted
to establish the mutagenic and genotoxic potential of p-mentha-
1,8-dien-7-al, including updated mutagenicity studies in bacteria
(Ames assays) and in mammalian cells (an hprt assay), and a
micronucleus assay in human blood lymphocytes. These studies are
described in detail in a recent publication (Hobbs et al., 2016), but
the data are summarized here to provide a comprehensive over-
view of the available genotoxicity data for perillaldehyde.
2.2.1. In vitro
An Ames assay was conducted in S. typhimurium strains TA98,
TA100, TA1535, TA1537 and TA102, both in the absence and in the
presence of metabolic activation S-9 (from Aroclor 1254-induced
rat livers) in three separate experiments (Bowen, 2011; Hobbs
et al., 2016). p-Mentha-1,8-dien-7-al cytotoxicity was determined
in the TA100 strain using the plate incorporation method at con-
centrations of 1.6, 8, 40, 200, 1000 and 5000 mg/plate, in the pres-
ence and absence of S-9. Toxicity was observed at 5000 mg/plate in
the absence and presence of S-9 and adequate data were obtained
for mutation analysis in strain TA100. p-Mentha-1,8-dien-7-al was
tested in the other four tester strains at concentrations of 0.32, 1.6,
8, 40, 200, 1000 and 5000 mg/plate, with toxicity observed at 1000
and 5000 mg/plate in all strains with and without S-9, and in a
second experiment, at 8.92, 20.48, 51.2, 128, 320, 800, 2000, and
5000 mg/plate, including a 60 min pre-incubation step in the
presence of S-9, with toxicity observed in all strains at either 320,
800, or 2000 mg/plate and above in the absence and presence of S-9.
Increased revertant frequency was observed in strain TA98 in the
absence of S-9 activation in both experiments (at 200 and 1000 mg/
plate in the ﬁrst experiment and at 320 and 800 mg/plate in the
second). Other strains did not demonstrate any increases in
revertant frequencies. As the result in TA98 was both unexpected
and inconsistent with previous Ames assays, the test was repeated
in strain TA98 with a different batch of test article but the same
treatment conditions. Toxicity was observed at 5000 mg/plate in the
absence of S-9 and at all concentrations in the presence of S-9.
Unlike the previous two experiments where precipitation was
observed on all test plates at 5000 mg/plate, no precipitation was
seen at this concentration in the third experiment. However, as in
the previous two experiments, a statistically signiﬁcant and dose-
related increase in revertant numbers was observed for strain
TA98 at 8 mg/plate and above in the absence but not in the presence
of S-9 (Bowen, 2011) (see Table 1).
The mutagenicity of p-mentha-1,8-dien-7-al was also tested
with the hprt assay in mouse lymphoma L5178Y cells to clarify the
results of bacterial assays and to assess their relevance for
mammalian organisms (Lloyd, 2012; Hobbs et al., 2016). In this
assay, the induction of forward mutations at the hypoxanthine-
guanine phosphoribosyl transferase (hprt) locus was measured in
cells treated with p-mentha-1,8-dien-7-al at concentrations of 20,
40, 60, 70, 80, 90, and 100 mg/ml for 3 h in the absence of S-9, and
40, 60, 80, 100, 120, 140, 160, and 180 mg/ml in the presence of S-9.Table 2
Genotoxicity proﬁle of perillaldehyde e in vivo studies.
Test system Test object Route
Micronucleus assay Mouse bone marrow cells i.p.
Micronucleus assay Rat bone marrow cells oral
Comet assay Duodenum oral
Liver oralNo signiﬁcant increases in mutation frequency or statistically sig-
niﬁcant linear trends were observed up to toxic concentrations, as
relative survival (%RS) dropped to 13% at 100 mg/mL in the absence
of S-9 and to 16% at 180 mg/mL in the presence of S-9. In repeat
assays, cultures were treated with p-mentha-1,8-dien-7-al for 3 h
at 20, 40, 50, 60, 70, 80, 90, 100 and 120 mg/ml in the absence of S-9,
and at 25, 50, 75, 100, 120, 140, 160, 170 and 180 mg/ml in the
presence of S-9, and for 24 h at 4, 8, 12, 15, 18 and 21 mg/mL in the
absence of S-9. Relative survival (%RS) decreased to 7% at 120 mg/mL
in the absence and to 10% at 180 mg/mL in the presence of S-9 in the
3 h treatments and to 9% in the 24-h treatment. There was no
statistically signiﬁcant increase in mutation frequency under any
conditions tested, although a statistically signiﬁcant linear trend
was seen in the absence of S-9 (3- and 24-h treatments) in the
repeat assay. However, as this observation was not consistent be-
tween the two independent assays and in the absence of any in-
creases in mutant frequencies at any concentration or condition
analyzed, the linear trend alone is not considered biologically
relevant. Therefore, p-mentha-1,8-dien-7-al did not induce muta-
tions in this test system when tested up to toxic concentrations
(Lloyd, 2012; Hobbs et al., 2016).
p-Mentha-1,8-dien-7-al was also tested in an in vitro micronu-
cleus assay for the induction of chromosome damage in cultured
humanperipheral blood lymphocytes (whole blood cultures pooled
from 2 healthy male volunteers), in the absence and presence of rat
liver metabolizing system (S-9), according to OECD Guidelines
(Lloyd, 2009; Hobbs et al., 2016). p-Mentha-1,8-dien-7-al was
added 48 h following culture stimulation by phytohaemagglutinin
for either 3 h at concentrations of 80, 110, and 120 mg/ml without S-
9, and 100, 120, and 140 mg/ml with S-9, or for 24 h at concentra-
tions of 20, 25, and 35 mg/ml in the absence of S-9. Cytochalasin B
(6 mg/ml), to block cytokinesis, was added either at the start of
treatment (24-h treatments) or at the start of recovery. Cytotoxicity
at the top concentration in each treatment reached 58, 45% and
58%, respectively, i.e., within the target range of 50e60%. There
were no statistically signiﬁcant differences between the fre-
quencies of micronucleated binuclear (MNBN) cells in treated cul-
tures compared to controls; all frequencies were similar to those of
concurrent vehicle controls and fell within (or slightly below)
historical control ranges. Therefore, p-mentha-1,8-dien-7-al was
clearly negative for genotoxicity in this assay (Lloyd, 2009). The
different outcome between this assay and the earlier positive CA
tests may be explained by the fact that human cells but not CHO/
CHL are p53-competent, or that different measures of cytotoxicity
were used and the extent of cytotoxicity was different. Any con-
cerns would normally be resolved by robust in vivo testing for
clastogenicity.
2.3. Conclusions from in vitro and older in vivo genotoxicity testing
for p-mentha-1,8-dien-7-al
Taken together, inconsistent results were reported in earlier
assays, including the sister chromatid exchange assay (SCE), the
chromosomal aberration test (CA), rec-assay, and mutagenicity
tests. In more recent studies, p-mentha-1,8-dien-7-al wasDose
mg/kg bw
Result Reference
75, 150, 300, and 600 Negative Hayashi et al. (1988)
175, 350, and 700 Negative Bowen (2011)
175, 350, and 700 Negative
175, 350, and 700 Negative
Fig. 1. Recognized metabolism of p-mentha-1,8-dien-7-al in mammals.
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presence of S-9), and negative in the other Salmonella strains under
all conditions. It was not mutagenic in the hprt assay using the
mouse lymphoma cell line L5178Y up to toxic concentrations in the
presence and absence of S-9. Therefore, the mutagenic effect of p-
mentha-1,8-dien-7-al seen in TA98 without metabolic activation
does not appear to be biologically relevant for mammalian cells. In
addition, p-mentha-1,8-dien-7-al was negative for chromosomal
damage in an earlier in vivoMN assay using a single intraperitoneal
injection, and in a recent, OECD Guideline-compliant in vitro MN
assay in human blood lymphocytes. The fact that it is not clasto-
genic in robust in vitroMN assays raises doubts about the relevance
of the previously collected in vitro CA assays that gave positive
results.
In mammals (rabbits and rats), p-mentha-1,8-dien-7-al follows
metabolic pathways common to other monocyclic (e.g., 2,6,6-
trimethyl-1-cyclohexen-1-carboxaldehyde) aldehydes that
contain alkyl ring substituents, primarily involving oxidation to the
corresponding carboxylic acid (e.g. perillic acid), conjugation with
glucuronic acid, and excretion in the urine (Ishida et al., 1989; Boon
et al., 2000). In a minor pathway, the aldehyde may be reduced to
the alcohol which is excreted as the glucuronide conjugate (Ishida
et al., 1989; Haag and Gould, 1994). Alternate pathways include
reduction of the endocyclic double bond by gut microﬂora or
aromatization of the acid metabolite to yield a benzoic acid deriv-
ative (p-isopropylbenzoic acid), which may be excreted as the
glycine conjugate (Fig. 1) (Ishida et al., 1989). Taking into account
the above genotoxicity results and considering the fact that p-
mentha-1,8-dien-7-al and related substances are rapidly metab-
olised in vivo to compounds of lower toxicological potential, one
could reasonably conclude that based on the previously available
data and that collected since 2010, p-mentha-1,8-dien-7-al is of no
concern with respect to genotoxicity.
All the evidence described above was ﬁrst reviewed by EFSA in
2013 and published in Flavoring Group Evaluation 208 (FGE.208) as
part of the re-evaluation of ﬂavoring substances belonging to the
chemical group of alicyclic aldehydes with the a,b-unsaturation in
ring or side-chain (EFSA, 2013). The EFSA Panel concluded that the
overall evidence was insufﬁcient to exclude genotoxicity concerns
for p-mentha-1,8-dien-7-al and related substances. Remaining
doubt and uncertainty, likely driven by the evidence of mutage-
nicity obtained in the recently conducted Ames assay, led EFSA to
request a more deﬁnitive study, speciﬁcally an in vivo comet assay
conducted according to OECD Guidelines and with analysis of
comet effects in the liver and duodenum.
2.4. Combined in vivo liver and duodenum comet assay and bone
marrow micronucleus study
An in vivo comet assaywas conducted in rats with analysis in the
liver as well as in the duodenum (the latter as a ﬁrst site of contact,
and also to address the fact that the results considered positive in
the Ames assay were collected in the absence of metabolic activa-
tion), in combination with a micronucleus assay with analysis of
micronucleus induction in polychromatic erythrocytes (PCE) of the
bone marrow (Beevers, 2014; Hobbs et al., 2016). This combination
assay was designed to address any remaining concerns for the DNA
damaging potential of p-mentha-1,8-dien-7-al while also address-
ing the discrepancy between the results of older assays and the
more recent in vitro micronucleus assay that was negative (Lloyd,
2009). Young male, out-bred Han Wistar (Crl:WI(Han)) rats (6/
dose) were administered p-mentha-1,8-dien-7-al by oral gavage at
dose levels of 175, 350 and 700 mg/kg bw/day (up to the maximum
tolerated dose in males; MTD) on three consecutive days, along
with vehicle control and positive (ethyl methanesulfonate; EMS;150 mg/kg bw) control groups. The top dose induced severe clinical
signs of toxicity (decreased activity, ataxia, piloerection and prone
posture) in female animals in a range-ﬁnding experiment (MTD for
females was 500mg/kg bw/day), but since the difference in toxicity
response between males and females was less than 2-fold, the
study was conducted in male rats only (as recommended in the
OECD Guideline). Signs of toxicity in the main study, indicated by
decreased activity in 5/6 animals and ataxia and piloerection in
single animals, were noted only at the top dose of 700 mg/kg bw/
day. Animals were sacriﬁced 3h after the last dose administration
and were subject to full necropsy. In addition, the study included
body weight and clinical chemistry parameters measurement and
liver histopathology (see Table 2).
Slightly increased enzyme activities of aspartate aminotrans-
ferase and alanine aminotransferase at the highest dose level,
indicative of liver injury and consistent with hepatocyte vacuola-
tion noted in histopathological examination conﬁrmed that p-
mentha-1,8-dien-7-al was tested up to toxic levels. Overall, the
study complied with all Guideline validity criteria.
In the micronucleus assay, there was no evidence of bone
marrow toxicity, based on the numbers of polychromatic erythro-
cytes. In addition, no evidence of genotoxicity was found, as sta-
tistically signiﬁcant increases in mean MN PCE frequencies were
lacking at any dose level compared to concurrent vehicle controls
and all values were within the historical control range. Therefore p-
mentha-1,8-dien-7-al was clearly negative for induction of micro-
nuclei in the bone marrow of treated rats.
In the comet assay, there was no excessive liver damage (me-
chanical or necrotic) as indicated by %clouds and %cells with halos,
and therefore, the liver toxicity noted above at the top dose did not
interfere with the validity of the assay. Group mean tail intensity or
tail moment in cells of rats treated with 175 and 350 mg/kg bw/day
were comparable to those of the control (150 cells per animal) and
all values fell within the historical control range in all treated and
control animals. A small but statistically signiﬁcant increase in the
group mean tail intensity was observed at the highest dose level
compared to the concurrent control group, although all values
remained within the historical control range. This small size of
increase and the absence of an effect at the next lower dose suggest
an indirect mode of action secondary to tissue toxicity, rather than
the result of direct genotoxicity, and therefore subject to a dose
threshold for liver toxicity. In the duodenum, there were no
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values were within the historical control range. This result directly
addresses uncertainties about small increases in genotoxicity as-
says in the absence of metabolic activation, since it reﬂects the
direct action of p-mentha-1,8-dien-7-al at the site of contact.
3. Criteria of assessment for the in vivo comet assay
According to OECD TG 489 guidelines, paragraph 59 (clearly
positive results), a positive result in the comet assay requires all
acceptability criteria to be met and when not, paragraph 62
(neither clearly negative nor positive) offers some guidance (OECD
TG 489):
“Evaluation and Interpretation of Results.
(Paragraph 59) Providing that all acceptability criteria are fulﬁlled,
a test chemical is considered to be clearly positive if:
a) at least one of the test doses exhibits a statistically signiﬁcant
increase compared with the concurrent negative control,
b) the increase is dose-related when evaluated with an appropriate
trend test,
c) any of the results are outside the distribution of the historical
negative control data for a given species, vehicle, route, tissue, and
number of administrations.
When all of these criteria are met, the test chemical is then
considered able to induce DNA strand breakage in the tissues
studied in this test system. If only one or two of these criteria are
satisﬁed, see paragraph 62.
(Paragraph 62) In case the response is neither clearly negative nor
clearly positive (i.e. not all the criteria listed in paragraphs 59 or
602 are met) and in order to assist in establishing the biological
relevance of a result, the data should be evaluated by expert
judgement and/or further investigations conducted, if scientiﬁcally
justiﬁed. Scoring additional cells (where appropriate) or perform-
ing a repeat experiment possibly using optimised experimental
conditions (e.g. dose spacing, other routes of administration, other
sampling times or other tissues) could be useful.”
Further to the above criteria, the biological relevance of results is
especially critical to assess in light of positive or equivocal results,
as stated in the Guideline:
“To assess the biological relevance of a positive or equivocal result,
information on cytotoxicity at the target tissue is required (see
paragraphs 54e55). Where positive or equivocal ﬁndings are
observed solely in the presence of clear evidence of cytotoxicity, the
study would be concluded as equivocal for genotoxicity unless
there is enough information that is supportive of a deﬁnitive
conclusion.”
Indeed, the EFSA Scientiﬁc Committee (EFSA, 2011) and others
(ICH, 2011) recommend a “weight-of-evidence” approach to reach a
complete and accurate evaluation and interpretation of genotox-
icity data. The weight-of-evidence approach considers not only the
quality and reliability of the genotoxicity assay data, but also any
relevant data, including physicochemical properties, structure-
activity relationships and ‘read-across’ from structurally related
substances, bioavailability, toxicokinetics and metabolism, and
evidence from chronic repeated-dose toxicity and carcinogenicity2 Note: paragraph 60 lists criteria that must be met for a clearly negative result.studies. In this context, the FEMA Expert Panel suggests that three
critical questions must be considered for the correct interpretation
of test results within the overall body of evidence and adherence to
Guideline criteria:
 Is there evidence for a consistent biological mechanism of
genotoxicity among assays?
 Are the effects reproducible?
 Is the evidence obtained from genotoxicity assays biologically
relevant within the broader body of evidence (e.g. outcomes of
carcinogenicity studies)?
These questions are similar to the criteria in the ICH Technical
Requirements for Registration of Pharmaceuticals for Human Use
(ICH, 2011), and have been considered relevant to serve as a guide
in the discussion that follows regarding the different interpretation
of the results of the most recent in vivo genotoxicity study (Beevers,
2014) within the overall weight-of-evidence of genotoxicity for p-
mentha-1,8-dien-7-al.
4. Recently published EFSA opinion on the genotoxicity of
p-mentha-1,8-dien-7-al
The comet/micronucleus combination assay for p-mentha-1,8-
dien-7-al was recently reviewed by the EFSA Panel on Food Con-
tact Materials, Enzymes, Flavourings and Processing Aids (CEF), and
the result of the evaluation was published in a recent Scientiﬁc
Opinion (EFSA, 2015). The Panel concluded that there is a safety
concern for its use as ﬂavoring substance based on the positive
ﬁnding in the liver comet assay. In addition, since p-mentha-1,8-
dien-7-al was considered as a ‘representative’ substance for 10
other substances, it was also concluded that there is a potential
safety concern for the other substances as well.
EFSA issued a press release (23/07/2015) entitled “Flavoring
substance considered a safety concern,” stating:
“The ﬂavouring substance p-mentha-1,8-dien-7-al (also called
“Perilla aldehyde”) has been shown to be genotoxic (damaging to
DNA) in a new study in animals, evaluated by EFSA's experts. Under
EFSA's process for the safety assessment of food ﬂavourings, once a
substance is characterised as a genotoxin, EFSA concludes on this
aspect only without taking into account consumer exposure.”
This conclusion reached by EFSA appears to be inconsistent with
the OECD Guideline criteria for interpretation of results of a comet
assay as described earlier. The Panel correctly concluded that the
other genotoxicity assays did not provide any evidence of geno-
toxicity for p-mentha-1,8-dien-7-al. The ﬁnal determination by
EFSA that p-mentha-1,8-dien-7-al is genotoxic was reached on the
basis of two of the three criteria for a positive test, namely the
statistically signiﬁcant difference between one treatment group
from its concurrent control group, and statistical evidence of dose-
response. A thorough and detailed examination of the scientiﬁc
data presented to the EFSA Panel leads one to a different conclusion
if the interpretation criteria were to be applied as intended.
More speciﬁcally, a key factor in the interpretation of the results
of the comet assay in the liver is the evidence of general toxicity and
hepatotoxicity at the highest dose tested. The lack of dose-related
increases in % clouds or % cells with halos in liver cells indicates
that treatment did not cause excessive DNA damage that could have
created artefacts and interfered with comet analysis. However,
other endpoints reveal evidence of dose-dependent general liver
toxicity in the test substance-exposed animals, and this effect was
particularly pronounced at the highest dose employed (700 mg/
kg bw/d), including a loss of body weight in the high dose group
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the group, elevated aspartate aminotransferase and alanine
aminotransferase and altered clinical biochemistry parameters
(cholesterol, potassium, chloride, urea and glucose); three animals
(numbered 27, 23 and 22) in the high dose group were particularly
affected. Histopathological examination (evaluated with identity of
group blinded) corroborated the clinical pathology ﬁndings with
observations of hepatocyte vacuolation in all 6 animals in the high
dose group. Additionally, 5 of the 6 animals in the high dose group
showed overt signs of toxicity reﬂected in their behavior (reduced
activity), particularly animals 27 and 23. The observed toxicity
in vivo is consistent with dose-dependent cytotoxicity of p-mentha-
1,8-dien-7-al seen in previously reported in vitro genotoxicity tests,
in the presence and absence of a metabolic activation system. The
dose-dependent cytotoxicity of p-mentha-1,8-dien-7-al was a
recurring characteristic of the material and was a limiting factor in
a number of these assays.
With regards to the parameters of the comet assay, interpreta-
tion of the results is guided by the three criteria set forth in the
OECD Guideline:
a) at least one of the test doses exhibits a statistically signiﬁcant
increase compared with the concurrent negative control” (OECD,
2014)
The EFSA Panel concluded that
“at the highest dose a 3.4-fold and statistically signiﬁcant increase
in tail intensity was observed. Five out of the six animals treated
with the highest dose had tail intensities that exceeded the values
observed in the concurrent vehicle control animals” (EFSA, 2015)
While this statement is correct, it should be pointed out that
only 2 of the 6 animals in this dose group, are driving the statisti-
cally signiﬁcant increase in group mean tail intensity, compared to
the concurrent vehicle control animals. More importantly, these
two animals were also among the three most affected by liver
toxicity (animals 27 and 23), indicating a direct association be-
tween liver toxicity and increased DNA tail intensities.
b) the increase is dose-related when evaluated with an appropriate
trend test,
The EFSA Panel stated that
“A statistically signiﬁcant linear trend was also apparent.” (EFSA,
2015)
While this statement is also accurate, this is also consistent with
the reported dose-dependent toxicity.
c) any of the results are outside the distribution of the historical
negative control data for a given species, vehicle, route, tissue, and
number of administrations. (OECD, 2014)
The EFSA Panel stated that
“… however, the tail intensity values for all animals fell within the
laboratory's historical control values.”
The observation that tail intensity values for all animals fell
within the laboratory's historical control values is pertinent and
under OECD TG 489 guidelines cannot be dismissed when consid-
ering the outcome of a comet assay.Additional elements of the study bear weight on the interpre-
tation of the results. The EFSA Panel noted that
“the range for both the negative and positive historical control
values were extremely wide for this test laboratory. In addition,
there was an overlap of the negative (95% range: 0.02e11.39) and
positive (95% range: 7.15e65.07) control values.” (EFSA, 2015)
This is indeed the case, but it is important to consider that the
tail intensity for the negative and positive controls of the speciﬁc
assay fell comfortably within the range of the historical control
values and near the means of the respective ranges: the positive
control tail intensity is close to the historical positive control mean
(35.55 ± 14.86). More importantly, the mean tail intensity of the
high dose group (700 mg/kg bw/d) of 2.20 ± 0.60 is comparable to
the historical negative control mean (2.22 ± 2.58), despite the skew
effected by animals 27 and 23.5. Conclusions
Overall, the pattern of DNA damage reported is described as a
statistically signiﬁcant increase in mean tail intensity only at the
high dose (compared to concurrent control) and a statistically
signiﬁcant linear trend, but also as a small scale of mean tail in-
tensity increase at the highest dose relative to the concurrent
control, a mean tail intensity in the low and middle dose groups
similar to the average of the historical control range, a mean tail
intensity driven by two animals in the group, and direct correlation
with clear biochemical and histopathological evidence of liver
toxicity. This pattern is consistent with a mode of action of DNA
damage secondary to cytotoxicity. Therefore, the ﬁnal conclusion
the EFSA Panel reached that “The comet arm of this study indicates
that p-mentha-1,8-dien-7-al induces DNA damage in liver” does not
follow the criteria as set in the OECD Guideline. First, it violates the
criteria for a positive test according to the Guideline, since the third
criterion for a positive comet assay has not been met and therefore
expert judgement is paramount. Second, where expert judgement
was called for, this conclusion dismissed the impact of toxicity on
the comet assay ﬁnding and lost sight of the absence of biological
relevance. It is clear that the positive result in the comet assay is
confounded by toxicity associated with treatment, particularly
evident at the high dose (700 mg/kg bw/d). According to OECD TG
489 guidelines, “it is not possible to distinguish DNA migration
induced by genotoxicity versus that induced by cytotoxicity in the
comet assay alone” and “Increases in DNAmigration in the presence of
clear evidence of cytotoxicity should be interpreted with caution”
(paragraph 54, OECD TG 489). In cases of confounded results the
Guideline proposes that “Changes in clinical chemistry measures (e.g.
AST, ALT), can also provide useful information on tissue damage and
additional indicators such as caspase activation, TUNEL stain, Annexin
V stain, etc.may also be considered” (paragraph 55, OECD TG 489). In
fact, the two animals (numbered 27 and 23) that drove the signif-
icant increase in tail intensity are also those with the most pro-
nounced evidence of hepatotoxicity.
In the view of the FEMA Expert Panel, any disregard for
consideration of the laboratory historical controls for this assay, and
for interpreting the data outside of the OECD guidelines is not
appropriate nor justiﬁed. For the reasons described above, we
concur with the conclusion of the authors of the comet assay report
(reproduced below for clarity) and agree that it is consistent with
the data and consonant with the OECD TG 489 Guideline:
“It is concluded that under the conditions of this study, p-Mentha-
1,8-dien-7-al did not induce an increase in micronucleated poly-
chromatic erythrocytes of the bone marrow of male rats following
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timate of the maximum tolerated dose for this study). A small but
statistically signiﬁcant increase in DNA damage in the liver was
detected in the comet assay following treatment with p-mentha-
1,8-dien-7-al at 700 mg/kg/day. However, as this increase was
concomitant with changes in liver enzymes and evidence of
perturbation of hepatocyte function, the DNA damage may be due
to a mechanism other than genotoxicity. No DNA migration was
observed [at] 175 or 350 mg/kg/day, where there was also no ev-
idence of liver toxicity.”
This assessment by the study authors is consistent with the
interpretation of the results by the FEMA Panel and not aligned
with that of EFSA, suggesting a possible need for re-evaluation of
the study to ensure that the OECD TG 489 Guideline is taken into
full account when the study is interpreted.
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